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Sex related risk of heart failure in suspected or known coronary artery 
disease: Adding a piece to the puzzle  
Cardiovascular disease represents the most common cause of death with a high mortality 
burden globally1. Over the recent years, sex related differences have been observed with 
cardiovascular disease affecting millions of women and accounting for four times more deaths 
than breast cancer2. Mortality rates are higher amongst women of older age and poor 
outcomes have been associated with failure of acknowledging the disease in the first place, 
although inadequate recognition and treatment has been correlated with high cardiovascular 
risk in young female individuals as well3,4.  
Studies have shown that despite the advanced treatment options of coronary artery disease 
(CAD), women that have suffered a myocardial infarction (MI) carry a higher risk of mortality 
and recurrent MI and have surprisingly lower rates of revascularisation after an acute event 
compared to their male counterparts5–7. Additionally, it has been demonstrated that women 
are at higher risk of developing heart failure following an acute MI, regardless of the severity 
of the coronary artery disease as determined by invasive angiography5. What then makes 
women more prone to the development of heart failure in the long term? Could they have 
higher ischaemic burden? Or do they have significantly impaired myocardium and lower left 
ventricular ejection fraction (LVEF) from the baseline that just worsens with time?  
In this issue of European Journal for Preventive Cardiology Núñez et al. present a very well 
contacted analysis adding a piece to this puzzle and seek to answer some of these questions8. 
The team have provided data from a large prospective registry that included 5,899 patients 
who underwent stress Cardiovascular Magnetic Resonance (CMR) imaging for known or 
suspected CAD over a period of fifteen years. Patients were followed up for a mean period of 
four and a half years. The main focus and primary clinical endpoint of the study was the risk 
of new-onset heart failure, an arguably underexamined endpoint in previously published data 
and studies. The diagnosis of new-onset heart failure was based on either an acute 
hospitalisation for heart failure or on the ambulatory heart failure diagnosis made by the 
physician in the outpatient setting according to the ESC guidelines9. The authors also analysed 
the impact of the ischaemic burden and left ventricular systolic function as assessed by CMR 
on the risk of new onset heart failure in both males and females.  
Women had significantly higher rates of new-onset heart failure during the entire follow up 
period, with the risk being 1.6 times higher than men. The strong correlation between female 
sex and higher risk of new-onset heart failure persisted even after multivariate adjustment 
accounting for the impact of competing events that included all-cause mortality, MI and 
revascularisation that took place during the follow-up period. Interestingly, the biggest 
proportion of the new-onset heart failure diagnoses in women was represented by acute 
heart failure hospitalisations rather than outpatient-based evaluation in the clinic setting. 
Although there were no statistically significant differences between men and women in terms 
of the ischaemic and necrosis burden as assessed by stress CMR, an important finding was 
noted regarding the LVEF. At reduced LVEF values, the risk of new-onset heart failure was 
high in both males and females. However, in the subgroup analysis of the patients with 
preserved LVEF defined as ≥55%, women had significantly higher incidence of new-onset 
heart failure.  
This real-life registry demonstrated that even after adjustment for all the traditional 
cardiovascular risk factors including age, revascularisation procedures and ischaemic burden, 
female sex remained independently associated with higher risk of new-onset heart failure in 
the context of known or suspected CAD. Moreover, baseline ventricular function plays a key 
role, with women with preserved EF exhibiting higher risk than their male counterparts.  
The authors should be congratulated for their study. Their findings however, generate 
important questions: What makes women with suspected or known CAD and preserved 
ejection fraction more likely to develop heart failure? Does this subgroup represent an 
underdiagnosed entity that is not treated with appropriate medical therapy and, 
subsequently, leads to increased rates of hospitalisation for heart failure? One cannot help 
but think of coronary microvascular dysfunction, a pathophysiological process that is 
increasingly gaining more interest as it is often missed and, subsequently, undertreated 
leading to increased incidence of cardiovascular events and hospitalisations10.  As part of the 
ischaemia with non-obstructive coronary arteries (INOCA), coronary microvascular 
dysfunction is often expressed with clinical symptoms suspicious of CAD in the absence of 
flow limiting coronary disease. Several large studies have unanimously demonstrated a 
significantly higher female prevalence of young and middle-aged groups10. Hospitalisation for 
heart failure with preserved ejection fraction is one of the most frequently encountered 
adverse events of coronary microvascular dysfunction with an observed incidence of up to 
ten times higher than asymptomatic women11. Despite the lack of evidence-based 
pharmacological therapy for improving prognosis, medical treatment with standard anti-
anginal medication is recommended, starting with beta-blockers, calcium channel blockers or 
ranolazine10. Answers to this question will come from them Women’s Ischaemia Treatment 
Reduces Events In Non-Obstructive CAD (WARRIOR) study (NCT03417388) comparing high-
intensity statin, ACE-Is or ARBs, and aspirin to usual care in 4422 symptomatic women with INOCA 
in a randomised multicentre setting.  
This study by Núñez et al. identifies the increased risk of subsequent heart failure in women 
with known or suspected CAD, particularly in those with preserved LVEF.  For medical 
professionals the results highlight the importance of close monitoring, early identification, 
appropriate investigations and prompt initiation of medical therapy in women, with a lower 
comparative threshold to men in those with preserved LVEF. Future research studies focusing 
on the pathophysiological mechanisms behind the observed findings can guide us with 
appropriately sex-tailored precise management of these patients.   
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